• Latest Posts

In the Age of Biological Therapeutics, Chemists move to ADCs

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Another Pharma sloughs off Small Molecules to focus on Biologics

Better than ADCs? AstraZeneca bids for Bicyclic Peptides

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer


Update: Yet Another ADC Company Makes Bank, This Time in Series B

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

#BioFigures: €406 Million Antibody-drug conjugate Deal struck by ImmunoGen andTakeda

Spirea raises £2.4M to develop antibody drug conjugates in cancer